tbuckley/cabot-search huggingface dataset:
Gemcitabine/docetaxel (GD) versus gemcitabine/cisplatin (GC) in stage III/IV non-small cell lung cancer (NSCLC): Preliminary results
Authors: M. Gamaz, T. Makhloufi, S. Taright, R. Baba-Ahmed, R. Amrane, K. Bouzid
Journal: Journal of Clinical Oncology (2006)

17116 Background: This study was designed to compare the response rates and toxicities of the standard GC regimen versus GD, a non-platin regimen, in locally advanced and metastatic NSCLC. Methods: In both arms, gemcitabine 1250 mg/m 2 was administered on days 1 and 8. In the GD arm, docetaxel 75 mg/m 2 was given on day 8. In the GC arm, cisplatin 70 mg/m 2 was given on day 1. Both regimens were repeated every 3 weeks. Results: From September 2004 to September 2005, 47 patients were enrolled In the GD arm (N = 25), the median age was 54.6 years (range, 45–70), and 22 (88.0%) were male. The majority of patients had either squamous cell (52.0%) or adenocarcinoma (44.0%), and stage IIIB disease (64.0%). In the GC arm (N = 22), the median age was 60.9 years (range, 42–74), and 20 (90.9%) were male. Most patients also had either squamous cell (50.0%) or adenocarcinoma (31.8%), and stage IIIB disease (59.1%). The difference in age between arms was significant (p = 0.046), but the differences in the remaining baseline characteristics and demographics were not significant. Toxicity and response results are in the table below. Conclusions: Overall response rate was numerically higher in the GC arm than the GD arm, but the difference was not significant because of the small sample size in each arm. The toxicity profile was significantly better in the GC arm for fatigue and nausea/vomiting. We think that GC regimen will remain the standard in treatment for advanced and metastatic NSCLC; however, we will confirm these findings in a randomized phase II study. [Table: see text] No significant financial relationships to disclose.
Are We Ready to Treat Diffuse Large B‐cell and High‐Grade Lymphoma According to Major Genetic Subtypes?
Authors: Annalisa Chiappella, Jennifer Crombie, Anna Guidetti, Umberto Vitolo, Philippe Armand, Paolo Corradini
Journal: HemaSphere (2019)

Abstract Diffuse Large B‐Cell Lymphoma (DLBCL) is a clinically and biologically heterogeneous disease. The revised Classification of Lymphoproliferative diseases published in 2016 (WHO, 2016) refined the previous DLBLC subtypes and identified four categories: DLBCL not otherwise specified (NOS), other lymphomas of large B cells, high grade B‐cell lymphoma, and B‐cell lymphoma unclassifiable. High grade B‐cell lymphomas include the entities carrying MYC, BCL2 and/or BCL6 translocations or cases with blastoid morphology without DH translocations. This classification also acknowledges the cell of origin (COO) classification, that has only a limited impact on the choice of frontline treatment for DLBCL, as most patients still receive R‐CHOP chemoimmunotherapy. Attempts to improve the outcomes of specific subgroups, especially COO groups, have so far had limited success. Newer analyses have further subdivided DLBCL into genomically distinct subsets, not yet incorporated in the WHO classification, which may facilitate targeted approaches to therapy. In this review, we discuss the subgroups that are recognized by the WHO 2016 classification, review the newer genomic data, and speculate on how this could alter the treatment landscape of DLBCL in the future. We also discuss novel approaches to salvage therapy in the broad context of the heterogeneity of DLBCL.
Characteristics of patients with prolonged survival after breast cancer brain metastases (BCBM).
Authors: Zorica Tomasevic, Zeljko Kovac, Zoran Tomasevic
Journal: Journal of Clinical Oncology (2013)

e20659 Background: BCBM development predicts short survival for majority of pts. However, 10%, of pts survive up to 2 yrs, and some of those pts has extended survival to more than 2 yrs after BM. Whether there are differences between pts in those arbitrary determined subgroups with prolonged survival is still unknown. The aim of this paper is to analyze and compare characteristics of BCBM pts with survival after BM (BMs) between ≥ 12 - 24 months and ≥ 25 month. Methods: A 193 consecutive BCBM pts have been registered during 5 yrs (January 2008-December 2012). All BM were confirmed by CT/MRI. All pts underwent BM treatment: WBRT 160 (83%); postoperative WBRT in 32 pts (17 %); gamma knife in 7 pts (3,6 %). BMs is known for 169 pts and was median 5,5 months (range 1-72+ months). Only pts with BMs ≥ 12 months were considered for this analysis. Results: 39/169 pts (23%) with median BMs 19 months (range 12-72+) were identified and divided in 2 groups (see Table). MBC in other organ sites, predominantly non visceral, was present in 45% pts (A) and in 40% (B), at the time of BM diagnose. There was no statistically significant difference between group A and B. Conclusions: Despite BM, a subgroup of pts still has indolent MBC course with median BMs of 19 months, and 6% has BMs of median 35 months. There were no statistically significant difference between standard clinical/pathological parameters Therefore, other characteristics, both patients and BC/BM must be considered. Better understanding of crucial characteristics of this subgroup of BCBM pts, is needed because these pts might potentially represents the best candidates for future BM preventive strategies. [Table: see text]
Do ascorbic acid and viscum album improve PFS in NSCLC?
Authors: Fatima Zehra Raza, Smita Ranjan, Goetz H. Kloecker
Journal: Journal of Clinical Oncology (2013)

3102 Background: Intravenous vitamin C achieves 70 times higher plasma concentrations of ascorbate as a similar oral dose. Such pharmacologic concentrations(0.3-20mM) kill cancer cells but not normal cells, through extracellular H 2 O 2 generation. Ascorbate treatment depleted ATP and induced autophagy in prostate cancer cells; gemcitabine with ascorbate resulted in 50% inhibition of growth in pancreatic tumor xenografts in mice models. A phase I/II study for pancreatic cancer patients is underway. Viscum album (mistletoe) is widely used in Europe as complementary therapy. Its cytotoxic and immunomodulatory effects are poorly understood. Additional treatment with subcutaneous mistletoe injections improved quality of life in gastric cancer patients in a study. Methods: We report the case of a 54 year old male smoker with adenocarcinoma of the lung (pT4N2M1a), EGFR/RAS/ALK negative. After 5 cycles of chemotherapy (carboplatin/taxol x 3, then carboplatin/pemetrexed x 2) scans showed continued progression. The patient made an informed decision to stop further chemotherapy and initiated complementary medical means, receiving high dose IV vitamin C (75 g, 2 x week) and subcutaneous mistletoe injections every other day, for the last seven months. Results: Six months into the non-standard therapy, a PET/CT shows a PR by RECIST and decreased FDG activity of the biopsy proven primary and metastatic site. The patient feels well, a year now after being diagnosed with advanced NSCLC. Conclusions: Whether the PR and the surprisingly long PFS is due to IV ascorbic acid and/or mistletoe is unknown. A review of the literature reveals reports of similar astonishing clinical results after treatment with either agent. A registry and biorepository of cases treated with alternative modalities may discover markers and biological mechanisms to explain these surprising reports.
Abstract 20164: Temporal Vascular Response to Novel, Long, Thin Strut Bioresorbable Scaffold in the Porcine Restenosis Model
Authors: Piotr P Buszman, Mateusz Kachel, Magdalena Michalak, Michal Jelonek, Adam Janas, Carlos Fernandez, Sanjeev Bhatt, Pawel E Buszman, Krzysztof Milewski
Journal: Circulation (2017)

Background: Treatment of long coronary lesions with bioresorbable scaffolds is currently limited to overlapping implantations only due to lack of long devices. Additionally, vascular response to lo...
Screening for Pancreatic Cancer Gets a D, but the Student Is Improving
Authors: Ralph H. Hruban, Keith D. Lillemoe
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Evaluation and Management of Obesity Hypoventilation Syndrome. An Official American Thoracic Society Clinical Practice Guideline
Authors: Babak Mokhlesi, Juan Fernando Masa, Jan L. Brozek, Indira Gurubhagavatula, Patrick B. Murphy, Amanda J. Piper, Aiman Tulaimat, Majid Afshar, Jay S. Balachandran, Raed A. Dweik, Ronald R. Grunstein, Nicholas Hart, Roop Kaw, Geraldo Lorenzi-Filho, Sushmita Pamidi, Bhakti K. Patel, Susheel P. Patil, Jean Louis Pépin, Israa Soghier, Maximiliano Tamae Kakazu, Mihaela Teodorescu
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

Section:ChooseTop of pageAbstract <<ContentsOverviewIntroductionMethodsHow to Use These Guidelin...ResultsDiscussionReferencesCITING ARTICLES
Ovarian cancer stem cells (OCSCs): Therapy for advanced chemoresistant ovarian cancer.
Authors: Prattusha Sengupta, Sudeshna Gangopadhyay, Saubhik Sengupta, Ujjal Kanti Ray, Ashis Mukhopadhyay
Journal: Journal of Clinical Oncology (2013)

e16542 Background: Invasive and mesenchymal property of Ovarian Cancer Stem Cells (OCSCs)with CD44 + /CD133 + has made them promising target for targeted treatment. Chemotherapy treatment uses medicine to weaken and destroy cancer cells in body, including cells at original cancer site and any cancer cells that may have spread to another part of body. Chemotherapeutic drugs for advanced chemo-resistant ovarian cancer are yet to be well defined. Combination of drugs is also not fully known. Our objective is to define chemotherapeutic drugs and its action in OCSC which is the major reason for chemo resistance in case of advanced chemo-resistant ovarian cancer patients. Methods: A total of twenty biopsy proven advanced chemo-resistant ovarian cancer patients in the age group of 22-36 years were selected randomly and tested for CD44/CD133 via flow cytometry. Isolated OCSCs were cultured for ex vivo drug sensitivity towards platinum, anthracyclin, docetaxel, rapamycin, sunitinib, sorafenib and gefitinib. Correlation was drawn between cell differentiations, % of stem cells and drug response. Accordingly chemotherapy was designed for a particular patient. Results: We detected OCSCs in 90% of cases. Among positive samples ex vivo drug sensitivity was seen in 4(20%) to rapamycin, 1(5%) to sunitinib, 1(5%) to sorafenib, 1(5%) to gefitinib, 3(15%) to platinum, 1(5%) to anthracyclin, 1(5%) to docetaxel and rest showed no sensitivity to any drug. Conclusions: Thus primary aim to target OCSCs at onset of tumors in ovarian cancer patients to control metastasis and relapse of disease was somewhat obtained. Most interestingly, we found that the chemotherapeutic drugs which were less prescribed for ovarian cancer showed greater sensitivity in comparison to the widely used ones. We like to do animal model study followed by phase I, II and III human clinical trial to establish our hypothesis for better management of chemo-resistant ovarian cancer.
Relative Value Units and the Measurement of Physician Performance
Authors: Michael Nurok, Bruce Gewertz
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 922: Preclinical anticancer activity of LSZ102, a novel oral selective estrogen receptor degrader targeting wild-type and mutant ER
Authors: L. Alex Gaither, Choi Lai Tiong Yip, Chunrong Wang, Weiyi Toy, Qing Sheng, Jinyun Chen, Yuji Mishina, Rita Das, Stefan Peukert, Alice Loo, Sarat Chandarlapaty, Adam Crystal, Tinya J. Abrams
Journal: Cancer Research (2019)

Abstract Estrogen receptor (ER) blockade is a well-established therapeutic approach in ER+ breast cancer. A novel oral selective estrogen receptor degrader (SERD), LSZ102, is in development. LSZ102 induces proteasome-mediated degradation of both wild type and mutant ERα in MCF-7 cells. LSZ102 also inhibits transcription of ERα target genes and results in a decrease in cell proliferation in a dose dependent manner. Expression of ERα Y537S results in a shift in inhibition of cell proliferation upon incubation with either LSZ102 or fulvestrant; however, the shift with LSZ102 was less severe. Similarly, LSZ102 induced a more pronounced level of ERα degradation than fulvestrant in the Y537S mutant MCF7 cells. Overall, LSZ102 is effective in the wild type and Y537S ERα mutant setting in vitro. In vivo, LSZ102 treatment of ER+ breast cancer xenografts resulted in inhibition of ERα regulated transcripts and a decrease in ERα protein levels. In the MCF7 xenograft model, expression of ERα Y537S resulted in reduced activity by fulvestrant, but not by LSZ102. In vivo, LSZ102 exhibited single agent and combination efficacy upon co-administration with the CDK4/6 inhibitor ribociclib and the alpha-specific PI3K inhibitor alpelisib. LSZ102 is currently in a Phase I clinical trial in patients with ER+ breast cancer in which it is tested as a single agent, and in combination with either ribociclib or alpelisib. Citation Format: L. Alex Gaither, Choi Lai Tiong Yip, Chunrong Wang, Weiyi Toy, Qing Sheng, Jinyun Chen, Yuji Mishina, Rita Das, Stefan Peukert, Alice Loo, Sarat Chandarlapaty, Adam Crystal, Tinya J. Abrams. Preclinical anticancer activity of LSZ102, a novel oral selective estrogen receptor degrader targeting wild-type and mutant ER [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 922.
The combination of intravenous bevacizumab and metronomic oral cyclophosphamide for recurrent platinum-resistant ovarian cancer.
Authors: Emma L. Barber, Nikki Lynn Neubauer, Emese Zsiros, Julian C. Schink
Journal: Journal of Clinical Oncology (2012)

5039 Background: This study was undertaken to determine the progression free survival and overall survival in heavily pre-treated patients with recurrent ovarian carcinoma treated with bevacizumab and metronomic oral cyclophosphamide. Methods: An IRB-approved retrospective review was performed for all patients with recurrent ovarian, fallopian tube or primary peritoneal carcinomas treated with intravenous bevacizumab 10mg/kg every 14 days and oral cyclophosphamide 50mg daily between January 2006 and December 2010. Response to treatment was determined by change in disease status according to RECIST criteria and/or CA-125 levels. Results: Sixty-six eligible patients were identified with a median age of 58 years. Fifty-five patients (83%) originally had optimal cytoreduction and all were platinum resistant. Median time from diagnosis to beginning bevacizumab and cyclophosphamide was 36 months. Median number of prior chemotherapy treatments was 7.5 (range 3-16). Eight patients (12.1%) had side effects which required discontinuing bevacizumab and cyclophosphamide, most common were hypertension, proteinuria, and fatigue. There was one bowel perforation (1.5%). A complete response was noted in 7 patients (10.6%), partial response was seen in 21 patients (31.8%) with an overall response rate of 42.4%. Fifteen patients (22.7%) had stable disease and 23 (34.8%) had disease progression. Median progression free survival (PFS) for responders was 5 months (range 2-14) and 11 months (range 4-14) for those with a complete response. Median overall survival (OS) from start of bevacizumab and cyclophosphamide for responders was 20 months (range 2-56) and 9 months (range 1-51) for nonresponders. Conclusions: Bevacizumab and cyclophosphamide is an effective, well-tolerated chemotherapy regimen in heavily pre-treated patients with recurrent ovarian carcinoma which significantly improves PFS and OS in responders. Response rates were significantly better than the rates we have reported in this same group of patients receiving topotecan (22%) or liposomal doxorubicin (25%) and were superior to reported rates for single agent bevacizumab (18%) in patients with only 2-3 prior regimens.
Hugh Shuter Platt
Authors: Gifford Batstone
Journal: BMJ (2019)

Hugh Shuter Platt entered University College Hospital in 1953. He was an exceptionally able student, gaining a distinction in surgery in his final exam and a first in his anatomy BSc. In 1960, he became a registrar and then lecturer in histopathology at University College Hospital in Ibadan, Nigeria, where he demonstrated—against then current beliefs – that Nigerian premature babies did develop hyaline membrane disease. This work gained him his MD. He considered his time at Ibadan as the most formative of his life and gave his two daughters Nigerian names.

On returning to England in 1965, Hugh was lured into chemical pathology by Professor Flynn at UCH, who recognised his tremendous organising talents. He was appointed consultant chemical pathologist at UCH in 1971, and he and Flynn designed the first pathology computer system.

In …
Hong Kong healthcare workers join protests
Authors: Jane Parry
Journal: BMJ (2019)

Thousands of healthcare workers in Hong Kong have rallied to protest against what they see as excessive use of violence by the police during the ongoing protest movement in the territory and to show that they stand with the Hong Kong public. Some have also been volunteering to treat injuries in the protest zones and to provide off-site medical care to people who fear arrest if they seek treatment in hospital.

The protests began in early June to oppose a proposed law that would allow China to request extradition of Hong Kong citizens to China. They have since broadened to include calls for an independent commission of inquiry to examine alleged police violence, the introduction of universal suffrage as promised to Hong Kong under the 1984 Sino-British Joint Declaration, and other related demands.

Public demonstrations and acts of civil disobedience have continued every …
Bowel obstruction with stage IV cancer: The benefit of introduction of formal palliative care service.
Authors: Moshim Kukar, Adrienne Groman, Yashodhara K. Satchidanand, Amy I. Alvarez-Perez, Kelli B. Dunn, Valerie Francescutti
Journal: Journal of Clinical Oncology (2013)

e20573 Background: Patients with stage IV cancer and bowel obstruction (BO) present a complicated management problem. The aim of this study was to evaluate the role of introduction of an organized palliative care service in the management of this complex disease process. Methods: We conducted a retrospective analysis of all patients admitted to the Roswell Park Cancer Institute with stage IV cancer and BO after the institution of formal palliative care service (PS) in 2009. This cohort was compared to a group prior to 2009 (No Palliative care service Group; NPS). The two groups were compared with respect to demographics, comorbid conditions, DNR status, laboratory parameters, medical, surgical management, length of stay and disposition status. Results: 28 patients were identified in PS group as compared to 40 patients in NPS group. The 2 groups were similar in terms of age, gender, race, comorbid conditions, primary site of cancer, chemotherapy, radiation therapy and weight loss. There was a statistically significant difference in the medication regimen provided, as those who had palliative care consults were more likely to receive alternative medications to standard anti-emetics (Table). The palliative care team followed 19/28 patients and 14/19 patients showed improvement in their symptoms (nausea, pain control) in initial 24 hours after the palliative care consult. 50 % ( n=14) of patients in PS group had a formal DNR order in place as compared to 15.4% in NPS group (p&lt;0.001). In 9/14 patients the first discussion regarding DNR was held by palliative care team. A significantly higher percentage of patients were discharged to the hospice care in PS group (42.9% vs. 7.5%, p =0.006). Conclusions: BO in patients with stage IV cancer often poses a dilemma in the choice of surgery versus medical management. Palliative care consults, early in the hospitalization, may help improve symptom management, end of life discussions, better psychosocial support, discharge placements and will eventually translate to shorter length of stay. [Table: see text]